SAFETY AND EFFICACY OF NEBULIZED ALBUTEROL IN VENTILATED PREMATURE INFANTS (HUMAN

雾化沙丁胺醇在通气早产儿（人类）中的安全性和有效性

• 批准号: 3887345
• 负责人: DALE C ALVERSON
• 金额: --
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3887345
• 关键词: beta adrenergic agent; bronchodilators; cardiac output; clinical trials; high frequency ventilation; human subject; human therapy evaluation; inhalation drug administration; lung disorder; oxygen consumption; patent ductus arteriosus; placebos; premature infant human; respiratory disorder chemotherapy; respiratory distress syndrome of newborn; respiratory function

This study will examine the cardiopulmonary effects of nebulized albuterol in 20 infants with hyaline membrane disease who have early evidence of chronic lung disease. On two consecutive days each infant will receive nebulized albuterol at a dose of 1.0 mg or placebo in a double-blind cross-over fashion. Vital signs, pulmonary mechanics, cardiac output, cardiac function, presence of a patent ductus arteriosus, and oxygen consumption will be measured before and sequentially for 6 hours after administration of placebo or albuterol.

这项研究将检查雾化沙丁胺醇对心肺功能的影响 在20名患有透明膜病的婴儿中， 慢性肺病 每名婴儿将连续两天 在一项双盲研究中，以1.0 mg剂量雾化沙丁胺醇或安慰剂 交叉时尚。 生命体征，肺力学，心输出量， 心脏功能、动脉导管未闭和氧气 将在之前和之后连续6小时测量消耗量 给予安慰剂或沙丁胺醇。